ArticleInfectious diseases and therapy2026
Predictive Utility of the Pediatric-EQUAL Scale in Pediatric Candidemia Admitted to PICU Association with Clinical and Microbiological Factors Related Mortality.
Article in Infectious diseases and therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Neonatal candidemia over seven years: Epidemiological trends, risk factors, and outcome associations with Paed-EQUAL Candida score adherence.European journal of pediatrics · 2026Article
- Clinical Utility of the Paed-EQUAL Candida Score in Paediatric Candidemia: A Real-World Cohort Study.Mycoses · 2026Observational
- Epidemiology of source-related candidaemia and breakthrough candidaemia in intensive care units.BMC infectious diseases · 2026Article
Corrections and comments
- Erratum issued
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionCandidemia is a notable cause of morbidity and mortality in critically ill children. The Pediatric (Paed)-EQUAL scale, which includes 11 clinical and microbiological assessment parameters, was recently developed to improve guideline compliance in pediatric patients with candidemia. The aim of our study was to evaluate compliance with the Paed-EQUAL scale in pediatric patients with candidemia and to demonstrate its relationship with survival.
methodsWe retrospectively analyzed the clinical and microbiological characteristics and compliance with the Paed-EQUAL scale parameters of patients aged 1 month to 18 years who were diagnosed with candidemia and admitted to our pediatric intensive care unit over a 10-year period. Among the 117 candidemia cases identified, 103 were included in the study. We evaluated the associations between survival and various parameters, including the Paed-EQUAL score and candidemia-related clinical and microbiological characteristics.
resultsThe 30-day mortality rate in our cohort was 17.5%. The Paed-EQUAL score had a significant discriminatory ability for identifying mortality outcomes. In the entire cohort, patients with a score of ≥ 16.5 had a greater likelihood of survival (AUC 0.742; p = 0.001). Separate analyses for patients with and without central venous catheters (CVCs) revealed that the discriminatory performance increased to an excellent level (AUC 0.913) among those without CVCs, which was based on a lower optimal cutoff (≥ 12.5). Multivariable regression revealed that the presence of breakthrough candidemia was associated with 10.5-fold greater odds of mortality (OR 10.52, 95% CI 1.66-66.7; p = 0.013), whereas each 1-point increase in the Paed-EQUAL score was associated with 1.4-fold greater odds of survival (OR 0.703, 95% CI 0.53-0.89; p = 0.004). Individual Paed-EQUAL components had no significant predictive role in assessing mortality risk.
conclusionThe present study revealed that the Paed-EQUAL score can predict mortality in pediatric patients with candidemia. Patients with a Paed-EQUAL score of ≥ 16.5 had significantly higher rates of survival.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.